# US 2025/0082755 A1 · Chimeric antigen receptors for treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082755 A1
- Document ID: US20250082755A1
- Status: Published application
- Kind: A1
- Application number: 18/292,499
- Filed: 2022-07-29
- Published: 2025-03-13
- Earliest claimed: 2021-07-29
- Assignees: Vor Biopharma Inc.
- Applicants: Vor Biopharma Inc.
- Inventors: Rebecca Moeller; Tirtha Chakraborty; Julian Scherer
- Web page: https://patentgrep.com/patent/US20250082755A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4217: {Receptors for interleukins [IL]}
- A61K 40/4234: {Interleukins [IL]}
- A61P 35/02: specific for leukemia
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 14/5403: {IL-3}
- C07K 2319/03: containing a transmembrane segment
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are chimeric antigen receptors (CARs) with binding specificity for CD123. Nucleic acids, expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are also disclosed, and methods including the treatment of a hematopoietic malignancy or premalignancy characterized by the expression of CD123, e.g., leukemias such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

## Claims

### Claim 1

A chimeric antigen receptor (CAR), comprising
a. an interleukin-3 (IL-3) molecule or a CD123-binding fragment thereof;
b. optionally, a linker region,
c. optionally, a hinge region,
d. a transmembrane region,
e. optionally, at least one costimulatory signaling domain, and
f. a signaling domain.

### Claim 2 (depends on 1)

The CAR of claim 1, wherein the IL-3 molecule, or CD123-binding fragment thereof, comprises a substitution mutation at an amino acid position corresponding to K110, D101, K116, or a combination thereof.

### Claim 3 (depends on 1, 2)

The CAR of claim 1 or 2, wherein the IL-3 molecule, or CD123-binding fragment thereof, comprises a D101A mutation, a K116V mutation, a K116W, or a combination thereof.

### Claim 4 (depends on 1, 2, 3)

The CAR of any one of claims 1-3, wherein the IL-3 molecule, or CD123-binding fragment thereof, comprises a D101A mutation and a K116V mutation.

### Claim 5 (depends on 1, 2, 3, 4)

The CAR of any one of claims 1-4, wherein the signaling domain is a CD3 zeta signaling domain.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The CAR of any one of claims 1-5, wherein the CAR comprises at least one costimulatory signaling domain that is CD28, 4-1BB, and/or OX-40 costimulatory signaling domain.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The CAR of any one of claims 1-6, wherein the CAR comprises a CD28 costimulatory signaling domain.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The CAR of any one of claims 1-7, wherein the CAR comprises a 4-1BB costimulatory signaling domain.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The CAR of any one of claims 1-8, wherein the CAR comprises an OX-40 costimulatory signaling domain.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The CAR of any one of claims 1-9, wherein the transmembrane region is a human CD4 transmembrane region.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The CAR of any one of claims 1-9, wherein the transmembrane region is a human CD8 transmembrane region.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The CAR of any one of claims 1-9, wherein the transmembrane region is a human CD28 transmembrane region.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The CAR of any one of claims 1-12, wherein the CAR comprises a hinge region that is a human immunoglobulin (Ig) subclass G4 (IgG4) fragment crystallizable (Fc) hinge region.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The CAR of any one of claims 1-13, wherein the CAR comprises a linker region that is a human immunoglobulin (Ig) subclass G4 (IgG4) fragment crystallizable (Fc) linker region.

### Claim 15 (depends on 14)

The CAR of claim 14, wherein the human IgG4 Fc linker region comprises a substitution mutation at an amino acid position corresponding to L235, N297 or a combination thereof.

### Claim 16 (depends on 14, 15)

The CAR of claim 14 or 15, wherein the human IgG4 Fc linker region comprises a L235E mutation, a N297Q mutation, or a combination thereof.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The CAR of any one of claims 1-16, wherein the CAR comprises, from N-terminus to C-terminus,
a. the interleukin-3 (IL-3) molecule or CD123-binding fragment thereof;
b. the linker region and/or a hinge region,
c. the transmembrane region, and
d. the signaling domain.

### Claim 18 (depends on 17)

The CAR of claim 17, wherein the CAR does not comprise a costimulatory signaling domain.

### Claim 19 (depends on 17, 18)

The CAR of claim 17 or 18, wherein the CAR comprises an amino acid sequence having at least 95% sequence identity to any one of SEQ ID NOs: 21, 27, 33, 35, 37, 39, 45, 47, 49, or 51.

### Claim 20 (depends on 16, 17)

The CAR of claim 16 or claim 17, wherein the CAR comprises an amino acid sequence of any one of SEQ ID NOs: 21, 27, 33, 35, 37, 39, 45, 47, 49, or 51.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The CAR of any one of claims 1-16, wherein the CAR comprises, from N-terminus to C-terminus,
a. the interleukin-3 (IL-3) molecule or a CD123-binding fragment thereof;
b. the linker region and/or a hinge region,
C. the transmembrane region, and
d. the one or more co-stimulatory signaling domains, and
e. the signaling domain.

### Claim 22 (depends on 21)

The CAR of claim 21, wherein the CAR comprises an amino acid sequence having at least 95% sequence identity to any one of SEQ ID NOs: 23, 25, 29, 31, 41, or 43.

### Claim 23 (depends on 21, 22)

The CAR of claim 21 or claim 22, wherein the CAR comprises an amino acid sequence of any one of SEQ ID NOs: 23, 25, 29, 31, 41, or 43.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The CAR of any one of claims 1-23, wherein the CAR further comprises a signal peptide/signal sequence.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A nucleic acid construct encoding the CAR of any one of claims 1-24.

### Claim 26 (depends on 25)

The nucleic acid construct of claim 25, wherein the nucleic acid construct further comprises a promoter sequence.

### Claim 27 (depends on 25, 26)

The nucleic acid construct of claim 25 or 26, wherein the nucleic acid is RNA.

### Claim 28 (depends on 25, 26)

The nucleic acid construct of claim 25 or 26, wherein the nucleic acid is DNA.

### Claim 29 (depends on 25, 26, 27, 28)

A vector comprising the nucleic acid construct of any one of claims 25-28.

### Claim 30 (depends on 29)

The vector of claim 29, wherein the vector is a DNA vector, an RNA vector, a plasmid, a lentivirus vector, an adenoviral vector or a retrovirus vector.

### Claim 31 (depends on 25, 26, 27, 28, 29, 30)

A cell comprising the nucleic acid construct of any one of claims 25-30.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A cell expressing the CAR of any one of claims 1-24.

### Claim 33 (depends on 31, 32)

The cell of claim 31 or claim 32, wherein the cell is an immune effector cell.

### Claim 34 (depends on 33)

The cell of claim 33, wherein the cell is a T-lymphocyte.

### Claim 35 (depends on 33)

The cell of claim 33, wherein the cell is a NK cell.

### Claim 36 (depends on 31, 32, 33, 34, 35)

A pharmaceutical composition comprising the cell of any one of claims 31-35.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

A method, comprising administering the CAR of any one of claims 1-24, the nucleic acid construct of any one of claims 25-28, the vector of claim 29 or claim 30, or the cell of any one of claims 31-35 to a subject in need thereof.

### Claim 38 (depends on 37)

The method of claim 37, wherein the subject has or has been diagnosed with a hematopoietic malignancy or pre-malignancy characterized by the expression of CD123 on malignant cells or pre-malignant cells.

### Claim 39 (depends on 38)

The method of claim 38, wherein the hematopoietic malignancy is acute myeloid leukemia (AML).

### Claim 40 (depends on 38)

The method of claim 38, wherein the hematopoietic malignancy is myelodysplastic syndrome (MDS).

### Claim 41 (depends on 37, 38, 39, 40)

The method of any one of claims 37-40, further comprising administering a population of hematopoietic cells, wherein the hematopoietic cells are genetically-engineered such that the gene encoding CD123 is engineered to reduce or eliminate the expression of CD123.

### Claim 42 (depends on 25, 26, 27, 28, 29, 30)

A method comprising introducing into a cell with the nucleic acid construct of any one of claims 25-28, or the vector of claim 29 or claim 30.

### Claim 43 (depends on 42)

The method of claim 42, wherein the cell is obtained from, or derived from, a subject prior to introducing the nucleic acid construct or vector.

### Claim 44 (depends on 43)

The method of claim 43, wherein the subject has or has been diagnosed with a hematopoietic malignancy or pre-malignancy characterized by the expression of CD123 on malignant cells or pre-malignant cells.

### Claim 45 (depends on 42, 43, 44)

The method of any one of claims 42-44, wherein the cell is an immune effector cell.

### Claim 46 (depends on 45)

The method of claim 45, wherein the cell is a T-lymphocyte.

### Claim 47 (depends on 45)

The method of claim 45, wherein the cell is a NK cell.

### Claim 48 (depends on 46, 47)

The method of claim 46 or claim 47, wherein the T lymphocyte or NK cell is activated and/or expanded ex vivo.

### Claim 49 (depends on 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 42-48, wherein the nucleic acid or vector is introduced into the cell by lentiviral transduction, retroviral transduction, adeno-associated viral transduction, DNA electroporation, RNA electroporation, or transposon electroporation.
